Table 1 Demographic characteristics among cases and controls.
Variable | Total (N) | Cases, n (%) | Controls, n (%) | ap-value |
|---|---|---|---|---|
Age (years) | 500 | |||
Mean ± SD | 60.5 ± 9.86 | 61.6 ± 11.4 | 0.103 | |
Range | 30–86 | 31–83 | ||
Gender | 500 | |||
Male | 401 (80.2) | 455 (91.0) | ||
Female | 99 (19.8) | 45 (9.0) | < 0.0001 | |
Smoking status | 500 | |||
Smokers | 398 (79.6) | 449 (89.8) | ||
Non-smokers | 102 (20.4) | 51 (10.2) | < 0.0001 | |
Pack years | 500 | |||
Mean ± SD | 20.82 ± 21.03 | 13.84 ± 11.27 | < 0.0001 | |
Histological types | 500 | |||
SQCC | 205 (41.0) | |||
ADCC | 203 (40.6) | |||
SCLC | 84 (16.8) | |||
Others | 6 (1.2) | |||
Unknown | 2 (0.4) | |||
Overall survival | 475 | |||
Dead | 356 (74.9) | |||
Alive | 119 (25.0) | |||
Staging | 475 | |||
I | 6 (1.2) | |||
II | 19 (4.0) | |||
III | 193 (40.6) | |||
IV | 257 (54.1) | |||
Unclassified | 25 (5.2) | |||
Tumor size | 475 | |||
Tx | 19 (4.0) | |||
T1 | 26 (5.4) | |||
T2 | 41 (8.6) | |||
T3 | 85 (17.8) | |||
T4 | 302 (63.5) | |||
Unknown | 27 (5.6) | |||
Lymph node | 475 | |||
Nx | 3 (0.6) | |||
N0 | 65 (13.6) | |||
N1 | 34 (7.15) | |||
N2 | 210 (44.2) | |||
N3 | 163 (34.3) | |||
N4 | 0 (0) | |||
Unknown | 25 (5.2) | |||
Metastasis | 475 | |||
Mx | 1 (0.2) | |||
M0 | 210 (44.2) | |||
M1 | 263 (55.3) | |||
Unknown | 26 (5.4) | |||
Performance status | 476 | |||
KPS (below 60) | 86(18.1) | |||
KPS (70–80) | 259(54.4) | < 0.0001 | ||
KPS (90–100) | 131(27.5) | < 0.0001 | ||
ECOG (0–1) | 476 | 214(44.9) | ||
ECOG (2) | 188(39.49) | < 0.0001 | ||
ECOG (3–4) | 74(15.54) | < 0.0001 | ||
Chemotherapy regimen | 354 | |||
Pemetrexed cis/carboplatin | 105(29.66) | |||
Irinotecan cis/carboplatin | 45(12.71) | |||
Docetaxel cis/carboplatin | 37(10.45) | |||
Paclitaxel cis/carboplatin | 82(23.16) | |||
Gemcitabine cis/carboplatin | 29(8.19) | |||
Ceretinib | 1(0.28) | |||
Others | 48(13.55) |
